TANDEM DIABETES CARE INC
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the quarter ended June 30, 2026, one of our directors adopted a “Rule 10b5-1 trading arrangement” as that term is defined in Item 408 of Regulation S-K, as set forth in the table below.
| Name and Position · Action · Adoption/ Termination Date · Rule 10b5-1(1) · Non-Rule 10b5-1(2) · Total Shares of Common Stock to be Sold · Expiration Date | |||||
|---|---|---|---|---|---|
| Christopher Twomey, Director | Adoption | May 19, 2026 | X | 1,700(3) | November 15, 2026 |
(1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
(2) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
(3) Mr. Twomey’s Rule 10b5-1 trading plan provides for the potential sale of up to 1,700 shares of common stock issuable upon the exercise of certain stock options set to expire on November 15, 2026.
Except as set forth above, during the quarter ended June 30, 2026, none of our officers (as defined in Rule 16a-1(f) under the Exchange Act) or directors adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as those terms are defined in Item 408 of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.